

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Belumosudil for treating chronic graft versus host disease after 2 or more lines of systemic therapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Currently, only 72% of patients from White, Caucasian, backgrounds can find the best possible stem cell tissue match from a stranger. This drops, significantly, to 37% for patients from a minority ethnic background. Mismatched, unrelated donors are consistently reported as a risk factor for cGVHD, which is an iatrogenic complication resulting from AlloHSCT. Therefore, it is plausible that cGVHD is more likely to occur in people from a minority ethnic background.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The draft remit and scope do not discriminate against these groups. Committee will decide the extent to which a NICE recommendation in this therapy area could have a positive impact on people protected by the equality legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes. The background section of the scope was updated to include reference to the fact that ethnic minority people may be more at risk of developing cGVHD due to the increased difficulty of finding matching donors.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Linda Landells.....

Date: 12 January 2023